W0 2011/000721 A1 I||||||||||||||||||||||||||||||||||||||||||||||||||||||||| - Questel
W0 2011/000721 A1 I||||||||||||||||||||||||||||||||||||||||||||||||||||||||| - Questel
W0 2011/000721 A1 I||||||||||||||||||||||||||||||||||||||||||||||||||||||||| - Questel
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
12. A compound according to claim 10 or 1 1 of formula<br />
wherein aj is 32 and J i s a t h i r d g e n e ratio n 2 , 2 '-<br />
bis(methoxyol)propanoic acid (bis-MPA) based dendrimer.<br />
13. Compounds of formula [X-Y] Z -Z (I) according to claims 1 to 6 , as a<br />
medicament for the treatment and/or prevention of HIV, Ebola, Dengue,<br />
Hepatitis C, SARS or tuberculosis infections.<br />
14. Compounds of formula [X-Y] aw -W (Ia) according to claim 7 as a<br />
medicament for the treatment and/or prevention of HIV, Ebola, Dengue,<br />
Hepatitis C, SARS or tuberculosis infections.<br />
15. Compounds of formula [X-Y] aj -J (Ib) according to claims 10 to 12 as a<br />
medicament for the treatment and/or prevention of HIV, Ebola, Dengue,<br />
Hepatitis C, SARS or tuberculosis infections.